Total raised
—
Stage
Pre-Funding
Founded
2018
Headcount
3
HQ
Bnei Brak
Sector
Health Tech & Life Sciences
About
CannaLean Biotechs is committed to the research and development of a proprietary formulation of cannabidiol (CBD) and chitosan that can potentially benefit millions of patients with dyslipidemia.
CannaLean uses a synthetic form of CBD, a non-psychotropic component of cannabis, with chitosan, a biocompatible, non-toxic, and non-immunogenic compound that enhances the potential of CBD to reduce lipid blood levels. The company's preliminary results show the effect of the formulation on cholesterol and triglyceride reduction.
CannaLean Biotechs was established in partnership with Mor Research Applications.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentMedical Cannabis
Technologies
BiologicalsHerbals
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticalsHealthcarePatients
Business model
B2B
Highlights
1 Patents
Tags
cannabismedical-cannabistreatmentsmetabolic-diseasepatientspharma-companiesvascularbiotechnology